Open AccessStevens-Johnson syndrome and concurrent hand foot syndrome during treatment with capecitabine: A case report
Author(s) -
Ha Rim Ahn,
Sangkyung Lee,
Hyun Jo Youn,
Seok-Kweon Yun,
Iljae Lee
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i17.4279
Subject(s) - medicine , capecitabine , foot (prosody) , surgery , dermatology , colorectal cancer , cancer , linguistics , philosophy
Capecitabine is used in combination with lapatinib as palliative treatment for human epidermal growth factor receptor 2 - positive metastatic breast cancer. The most frequently reported adverse events attributed to capecitabine include diarrhea, hyperbilirubinemia, and hand-foot syndrome (HFS). A number of cutaneous adverse events have been attributed to capecitabine, including Stevens-Johnson syndrome (SJS) as a rare and potentially life-threatening mucocutaneous condition. We report the first case involving concurrent SJS and HFS after capecitabine and lapatinib treatment.